- Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma.
- AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon.
- The global Hepatitis B Virus market is expected to reach $35.63 billion in 2030.
- Patent dispute ongoing over Moderna's Covid-19 Vaccine. Favorable ruling in favor of Arbutus from Federal Appeals Court would be huge news for the company as it relates to its patents for lipid nanoparticles.
For further details see:
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment